TY  - BOOK
TI  - Sphingolipids: From Pathology to Therapeutic Perspectives - A Themed Honorary Issue to Prof. Lina Obeid
SN  - 9783039439577
PY  - 2021///
CY  - Basel, Switzerland
PB  - MDPI - Multidisciplinary Digital Publishing Institute
KW  - Biology, life sciences
KW  - bicssc
KW  - Research & information: general
KW  - acid sphingomyelinase
KW  - albumin
KW  - allyl carbamate derivative
KW  - animal models
KW  - anxiety
KW  - anxiety-like behavior
KW  - apoptosis
KW  - Aspergillus fumigatus
KW  - astrocytes
KW  - autophagy
KW  - barrier dysfunction
KW  - beta-cells
KW  - calcium
KW  - cancer
KW  - cardioprotection
KW  - ceramidase
KW  - ceramidases
KW  - ceramide
KW  - ceramides
KW  - CLN3 disease
KW  - Cln3Δex7/8 mice
KW  - coronary flow
KW  - cortex
KW  - cystic fibrosis
KW  - cytokines
KW  - depression
KW  - depressive-like behavior
KW  - fingolimod
KW  - flupirtine
KW  - forebrain
KW  - G-protein-coupled receptors
KW  - gangliosides
KW  - Gαq/11
KW  - hippocampus
KW  - histone acetylation
KW  - hypothalamus
KW  - hypoxia
KW  - immunotherapy
KW  - infectious diseases
KW  - inflammation
KW  - insulin
KW  - insulin resistance
KW  - ischemia/reperfusion
KW  - islets
KW  - long non-coding RNA
KW  - metastasis
KW  - microRNA
KW  - multiple sclerosis
KW  - myocardial function
KW  - myocardial infarct
KW  - myriocin
KW  - n/a
KW  - neurodegeneration
KW  - neurodegenerative diseases
KW  - neurons
KW  - obesity
KW  - pancreatic β cell fate
KW  - phenotype switching
KW  - S1P
KW  - S1P receptor
KW  - S1P transporter
KW  - S1P-lyase (SGPL1)
KW  - S1P1-5
KW  - SK1
KW  - Smpd1
KW  - sphingolipids
KW  - sphingomyelinase
KW  - sphingosine 1-phoshate
KW  - sphingosine 1-phosphate
KW  - Sphingosine 1-phosphate (S1P)
KW  - sphingosine 1-phosphate antagonistst/inhibitors
KW  - sphingosine 1-phosphate metabolism
KW  - sphingosine 1-phosphate receptor
KW  - sphingosine 1-phosphate signaling
KW  - sphingosine kinase
KW  - sphingosine kinase 1
KW  - sphingosine-1-phosphate
KW  - Sphingosine-1-phosphate
KW  - spinster homolog 2
KW  - stroke
KW  - tau
KW  - transcription factor
KW  - type 1 diabetes
KW  - type 2 diabetes
KW  - vasoconstriction
N1  - Open Access
N2  - Although sphingolipids are ubiquitous components of cellular membranes, their abundance in cells is generally lower than glycerolipids or cholesterol, representing less than 20% of total lipid mass. Following their discovery in the brain-which contains the largest amounts of sphingolipids in the body-and first description in 1884 by J.L.W. Thudichum, sphingolipids have been overlooked for almost a century, perhaps due to their complexity and enigmatic nature. When sphingolipidoses were discovered, a series of inherited diseases caused by enzyme mutations involved in sphingolipid degradation returned to the limelight. The essential breakthrough came decades later, in the 1990s, with the discovery that sphingolipids were not just structural elements of cellular membranes but intra- and extracellular signaling molecules. It turned out that their lipid backbones, including ceramide and sphingosine-1-phosphate, had selective physiological functions. Thus, sphingolipids emerged as essential players in several pathologies including cancer, diabetes, neurodegenerative disorders, and autoimmune diseases. The present volume reflects upon the unexpectedly eclectic functions of sphingolipids in health, disease, and therapy. This fascinating lipid class will continue to be the subject of up-and-coming future discoveries, especially with regard to new therapeutic strategies
UR  - https://directory.doabooks.org/handle/20.500.12854/76606
UR  - https://mdpi.com/books/pdfview/book/4051
ER  -